Nancy Davis Joins Tharimmune Board of Directors

Tharimmune, Inc., a biotech company committed to innovative therapies for inflammation and critical medical needs, announced Nancy Davis's appointment to its Board of Directors. Davis, founder of Race to Erase MS and Cure Addiction Now, is known for her advocacy and fundraising efforts in medical research. Her work has significantly advanced multiple sclerosis (MS) treatment, particularly through the development of MS therapies like Ocrevus®. Her personal battle with MS began in 1991, leading her to raise over $56 million to support groundbreaking research.

Davis's advocacy extends to addiction treatment, where she co-founded Cure Addiction Now to address substance use disorder through advanced research. Tharimmune's Chairman Vincent LoPriore lauds her as an invaluable asset, especially as the company works on TH104, a therapy for the effects of weaponized fentanyl. Davis's dedication to patient-focused solutions aligns with Tharimmune's mission to tackle the opioid crisis and other medical challenges.